True. There were benchmarks to be met before closure of the buyout. Something must have been triggered to consummate the agreement closing 2Q. Could be that the results coming from the ABIVERTINIB studies have been outstanding. What about Brazil? I noticed that the Royalties were to be paid until the merger so will product be sold by Sorrento before the merger?
News 
Market Data 
Discover 
AI
